
    
      The study will consist of 3 periods: screening(up to 7 days), treatment and follow-up(up to 3
      months). Subjects are assigned in a 1:1 ratio to Anfibatide or placebo during plasma exchange
      with the use of a computerized randomization schedule. The administration is 5 IU/60kg
      intravenous infusion and 0.002 IU/kg/h continuous intravenous infusion. Plasma exchange as
      the main treatment method is performed daily on the 5th day of solstice and then adjusted to
      every other day. Fresh frozen plasma（FFP）and cryoprecipitate-reduced plasma are preferred.
      Subjects will receive the study drug immediately after daily plasma exchange.
    
  